Mariner’s Palvella Therapeutics PVLA Stock Holding History

Mariner’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58M	Buy	10,361 +5,941	+134%	+$721K	﹤0.01%	1635
2026 Q1	$551K	Sell	4,420 -7,195	-62%	-$751K	﹤0.01%	2424
2025 Q4	$1.22M	Sell	11,615 -9,107	-44%	-$777K	﹤0.01%	1813
2025 Q3	$1.3M	Buy	+20,722	New	+$924K	﹤0.01%	1718
2019 Q4	–	Sell	-813	Closed	-$222K	–	727
2019 Q3	$222K	Hold	813	–	–	﹤0.01%	670
2019 Q2	$306K	Hold	813	–	–	﹤0.01%	878
2019 Q1	$218K	Hold	813	–	–	﹤0.01%	935
2018 Q4	$173K	Hold	813	–	–	﹤0.01%	784
2018 Q3	$364K	Hold	813	–	–	0.01%	614
2018 Q2	$330K	Hold	813	–	–	0.01%	623
2018 Q1	$443K	Hold	813	–	–	0.02%	456
2017 Q4	$491K	Hold	813	–	–	0.02%	393
2017 Q3	$374K	Buy	+813	New	+$347K	0.02%	388

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Mariner's PVLA Position: Q2 2026 in Review

Mariner increased its Palvella Therapeutics (PVLA) stake by 134% in Q2 2026, buying an estimated $721K and bringing the position to 10,361 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

Mariner first reported a position in PVLA in Q3 2017 and has held it in 13 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Mariner held 10,361 shares of Palvella Therapeutics worth $1.58M as of Q2 2026.
Mariner bought 5,941 Palvella Therapeutics shares in Q2 2026, an estimated $721K.
Palvella Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #1635 holding.
Mariner first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 13 quarters since.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.